Van Hulzen Asset Management LLC Makes New $278,000 Investment in Zoetis Inc. (NYSE:ZTS)

Van Hulzen Asset Management LLC purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,605 shares of the company’s stock, valued at approximately $278,000.

Several other large investors have also made changes to their positions in ZTS. International Assets Investment Management LLC lifted its holdings in Zoetis by 40.7% in the 4th quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock worth $479,000 after purchasing an additional 703 shares in the last quarter. Aveo Capital Partners LLC purchased a new position in shares of Zoetis in the fourth quarter worth $225,000. Gryphon Financial Partners LLC boosted its position in shares of Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after acquiring an additional 322 shares during the last quarter. Jump Financial LLC purchased a new position in Zoetis during the fourth quarter valued at $339,000. Finally, Checchi Capital Advisers LLC grew its stake in Zoetis by 7.0% during the fourth quarter. Checchi Capital Advisers LLC now owns 3,131 shares of the company’s stock valued at $618,000 after acquiring an additional 204 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $200.00 price target on shares of Zoetis in a report on Tuesday, August 27th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Down 0.2 %

NYSE ZTS opened at $191.37 on Wednesday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market capitalization of $86.70 billion, a price-to-earnings ratio of 36.87, a PEG ratio of 2.90 and a beta of 0.88. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a fifty day moving average of $181.93 and a two-hundred day moving average of $174.31.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the previous year, the company earned $1.41 EPS. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.